| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| rifabutin | Capsule, hard | 150 mg | Anticipated | Available | Manufacturing | 1/02/2026 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 30/01/2026 |
| calcitonin salmon | Injection, solution | 100 IU/mL | Anticipated | Available | Unexpected increase in consumer demand | 30/01/2026 |
| topiramate | Tablet, film coated | 25 mg | Anticipated | Available | Manufacturing | 30/01/2026 |
| moclobemide | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 30/01/2026 |
| clevidipine | Injection, emulsion | 25 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 30/01/2026 |
| gabapentin | Capsule, hard | 300 mg | Current | Limited Availability | Manufacturing | 30/01/2026 |
| levetiracetam | Injection, intravenous infusion | 100 mg/mL | Anticipated | Available | Manufacturing | 30/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | .75 mg | Anticipated | Available | Manufacturing | 30/01/2026 |
| avanafil | Tablet, uncoated | 200 mg | Current | Limited Availability | Unexpected increase in consumer demand | 30/01/2026 |
| telmisartan~amlodipine besilate | Tablet, film coated | 40 mg~13.87 mg | Current | Limited Availability | Unexpected increase in consumer demand | 30/01/2026 |
| telmisartan~amlodipine besilate | Tablet, film coated | 40 mg~6.935 mg | Current | Limited Availability | Unexpected increase in consumer demand | 30/01/2026 |
| quetiapine fumarate | Tablet, modified release | 345 mg | Anticipated | Available | Unexpected increase in consumer demand | 30/01/2026 |
| lamotrigine | Tablet, chewable | 50 mg | Anticipated | Available | Manufacturing | 30/01/2026 |
| daunorubicin hydrochloride | Injection, powder for | 20 mg | Anticipated | Available | Manufacturing | 30/01/2026 |
| Interferon gamma1b | Injection, solution | 4 million IU/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 30/01/2026 |
| norethisterone~ethinylestradiol | Tablet, uncoated | 500 microgram~36 microgram | Current | Limited Availability | Manufacturing | 30/01/2026 |
| rifampicin | Oral Liquid | 20 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 29/01/2026 |
| atracurium besilate | Injection, intravenous infusion | 10 mg/mL | Resolved | Available | Manufacturing | 29/01/2026 |
| calcium polystyrene sulfonate | Powder | 999.3 mg/g | Resolved | Available | Manufacturing | 29/01/2026 |
| lidocaine | Spray, solution | 100 mg/mL | Current | Unavailable | Manufacturing | 29/01/2026 |
| dantrolene sodium hemiheptahydrate | Injection, powder for | 20 mg | Resolved | Available | Manufacturing | 29/01/2026 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Current | Limited Availability | Manufacturing | 29/01/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Resolved | Available | Manufacturing | 29/01/2026 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| isotretinoin | Capsule, soft | 20 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| phenobarbital | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| temozolomide | Capsule, hard | 20 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| ezetimibe~simvastatin | Tablet | 10 mg~40 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| midazolam | Injection, solution | 50 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| propofol | Injection, emulsion | 10 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 29/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Unexpected increase in consumer demand | 29/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| rifampicin | Capsule | 150 mg | Current | Emergency Supply Only | Manufacturing | 29/01/2026 |
| pregabalin | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| isotretinoin | Capsule, soft | 10 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| isotretinoin | Capsule, soft | 20 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| quetiapine fumarate | Tablet, modified release | 57.5 mg | Resolved | Available | Unexpected increase in consumer demand | 29/01/2026 |
| quetiapine fumarate | Tablet, modified release | 172.5 mg | Anticipated | Available | Unexpected increase in consumer demand | 29/01/2026 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 29/01/2026 |
| codeine phosphate hemihydrate | Oral Liquid | 5 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 29/01/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| cyproterone acetate | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 40 mg~12.5 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| cinacalcet hydrochloride | Tablet, film coated | 99 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| dabigatran etexilate mesilate | Capsule, hard | 172.95 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| dimethyl fumarate | Capsule, enteric | 240 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| aprepitant | Capsule, hard | 165 mg | Anticipated | Available | Manufacturing | 29/01/2026 |
| tamoxifen citrate | Tablet | 30.34 mg | Anticipated | Available | Manufacturing | 29/01/2026 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| isotretinoin | Capsule, soft | 20 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| lacosamide | Tablet, film coated | 100 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| temozolomide | Capsule, hard | 5 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| sodium nitroprusside | Injection, concentrated | 50 mg | Current | Unavailable | Commercial Changes / Commercial viability | 29/01/2026 |
| isotretinoin | Capsule, soft | 20 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 29/01/2026 |
| lidocaine hydrochloride | Injection, solution | 10 mg/mL | Anticipated | Available | Manufacturing | 29/01/2026 |
| nizatidine | Capsule, hard | 300 mg | Current | Limited Availability | Manufacturing | 29/01/2026 |
| chlorhexidine gluconate | Solution, irrigation | 30 mg | Current | Limited Availability | Manufacturing | 28/01/2026 |
| leflunomide | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 28/01/2026 |
| fluorouracil | Injection, solution | 5000 mg | Current | Unavailable | Unexpected increase in consumer demand | 28/01/2026 |
| pioglitazone hydrochloride | Tablet | 49.9 mg | Anticipated | Available | Manufacturing | 28/01/2026 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 28/01/2026 |
| rosuvastatin calcium | Tablet, film coated | 41.68 mg | Current | Unavailable | Manufacturing | 28/01/2026 |
| rosuvastatin calcium | Tablet, film coated | 10.42 mg | Current | Unavailable | Manufacturing | 28/01/2026 |
| rosuvastatin calcium | Tablet, film coated | 20.84 mg | Current | Unavailable | Unexpected increase in consumer demand | 28/01/2026 |
| pregabalin | Capsule, hard | 150 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/01/2026 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 27 mg~200 mg~100 mg | Resolved | Available | Unexpected increase in consumer demand | 28/01/2026 |
| ondansetron | Tablet, orally disintegrating | 4 mg | Current | Limited Availability | Manufacturing | 28/01/2026 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Limited Availability | Manufacturing | 28/01/2026 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 28/01/2026 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Current | Limited Availability | Manufacturing | 28/01/2026 |
| finasteride | Tablet, film coated | 1 mg | Resolved | Available | Manufacturing | 28/01/2026 |
| lamotrigine | Tablet, chewable | 50 mg | Anticipated | Available | Manufacturing | 28/01/2026 |
| flecainide acetate | Tablet | 50 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 28/01/2026 |
| sodium chloride | Injection, solution | 90 mg | Resolved | Available | Manufacturing | 28/01/2026 |
| lidocaine hydrochloride monohydrate | Injection, solution | 10 mg/mL | Resolved | Available | Manufacturing | 28/01/2026 |
| levodopa~carbidopa monohydrate | Tablet, uncoated | 100 mg~26.9 mg | Current | Limited Availability | Manufacturing | 28/01/2026 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 27 mg~200 mg~100 mg | Resolved | Available | Manufacturing | 28/01/2026 |
| salbutamol sulfate | Inhalation, conventional | 6 mg | Current | Unavailable | Manufacturing | 27/01/2026 |
| salbutamol sulfate | Inhalation | 2.4 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/01/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/01/2026 |
| oxycodone hydrochloride | Tablet, uncoated | 5 mg | Anticipated | Available | Manufacturing | 27/01/2026 |
| mesalazine | Suppository, moulded | 1000 mg | Current | Limited Availability | Manufacturing | 27/01/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 27/01/2026 |
| trientine dihydrochloride | Capsule | 250 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 27/01/2026 |
| progesterone | Pessary | 400 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 27/01/2026 |
| olipudase alfa | Injection, powder for | 20 mg | Anticipated | Available | Manufacturing | 27/01/2026 |
| dantrolene sodium hemiheptahydrate | Capsule | 25 mg | Current | Unavailable | Manufacturing | 27/01/2026 |
| dantrolene sodium hemiheptahydrate | Capsule | 50 mg | Current | Unavailable | Manufacturing | 27/01/2026 |
| mefloquine hydrochloride | Tablet, uncoated | 274.09 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 27/01/2026 |
2026年2月2日